PUBLIC POLICY STATEMENT

Organon’s Pharmaceuticals in the Environment (PiE) Program Position Statement

Pharmaceuticals in the Environment
- With the great benefit of more access to medicines around the world and expanded pharmaceutical supply chains, comes the increased potential for pharmaceuticals to enter the environment.
- Pharmaceuticals in the environment (PIE) are recognized as an international issue of concern by the World Health Organization and the United Nations Environment Program.
- Patient use, improper disposal of unused medicine, and manufacturing can contribute pharmaceuticals into local waters, soils, and communities.
- Pharmaceuticals in the environment could have potential impacts on communities and the environment without responsible management.

Organon’s PiE Mission Statement
- Organon is committed to the highest ethical standards – every day, in everything we do.
- We approach managing pharmaceuticals’ impacts on the environment by building collaboration, use of technical best practices, and transparency.
- We are taking action to minimize the environmental impact of our products, and support positive change for a healthy planet, essential to the health of women.

Organon’s PiE Position Statement
- We actively assess potential environmental risk from product development through the manufacturing process and certain aspects of patient use.
- We collaborate both internally and externally to support continued research to manage PiEs. We contribute toward and use industry best practices, tools, and resources. We support increased transparency to share research and information.
- We support research and innovations to evaluate and mitigate the potential environmental impacts of our products through their full life cycle.

How Organon meets these goals
- We assess potential risks and impacts on human health and the environment by completing Environmental Risk Assessments (ERAs) for all products. Our products meet the applicable regulations, including the regulatory review processes of the U.S. Food and Drug Administration and the European Medicines Agency.
- We use appropriate technologies and best practices to minimize the discharge of active pharmaceutical ingredients (APIs) at Organon manufacturing facilities. We monitor and evaluate our risk assessments and control measures for continuous improvement.
- We collaborate as a member of the Pharmaceutical Supply Chain Initiative (PSCI) with current and potential external partners and suppliers to assess and improve their environmental processes and procedures, and to promote the adoption and use of the PSCI principles and resources.
- We participate in industry initiatives, such as the Pharmaceutical Product Stewardship Work Group, that coordinate product stewardship programs to provide access to drug takeback and sharps disposal programs for consumers.
The health of women depends on the health of our planet. At Organon, we are working to implement environmentally friendly practices and long-term sustainability across our operations and across our industry’s value chain. These efforts help us contribute to positive change for women everywhere.